Difference between revisions of "Team:Jiangnan/Background"
| Line 132: | Line 132: | ||
<img src="https://static.igem.org/mediawiki/2018/2/29/T--Jiangnan--background_top.png" width="100%" style="margin-top: -15em;"> | <img src="https://static.igem.org/mediawiki/2018/2/29/T--Jiangnan--background_top.png" width="100%" style="margin-top: -15em;"> | ||
<h3 style="position: absolute; top: 1em; z-index: 1;margin-top: 1em;text-align: center; color: white;width: 100%">Background</h3> | <h3 style="position: absolute; top: 1em; z-index: 1;margin-top: 1em;text-align: center; color: white;width: 100%">Background</h3> | ||
| − | <div class="row " style="margin-top: | + | <div class="row " style="margin-top: 3em;"> |
<div class="col s8 offset-s2"> | <div class="col s8 offset-s2"> | ||
<p>Vaccine has been considered as one of the most cost-effective public health solution which could be used to prevent a large varieties of diseases. However, several factors such as high cost, unstable quality, weak supervision have been considerably limiting the development of the vaccine industry. Jiangnan team is thus motivated to reduce the cost of vaccine production through establishing a suspension cell line with self-owned intellectual for rapid production of a broad spectrum of viruses using synthetic biology approaches.</p> | <p>Vaccine has been considered as one of the most cost-effective public health solution which could be used to prevent a large varieties of diseases. However, several factors such as high cost, unstable quality, weak supervision have been considerably limiting the development of the vaccine industry. Jiangnan team is thus motivated to reduce the cost of vaccine production through establishing a suspension cell line with self-owned intellectual for rapid production of a broad spectrum of viruses using synthetic biology approaches.</p> | ||
Revision as of 09:56, 17 October 2018
Background
Vaccine has been considered as one of the most cost-effective public health solution which could be used to prevent a large varieties of diseases. However, several factors such as high cost, unstable quality, weak supervision have been considerably limiting the development of the vaccine industry. Jiangnan team is thus motivated to reduce the cost of vaccine production through establishing a suspension cell line with self-owned intellectual for rapid production of a broad spectrum of viruses using synthetic biology approaches.
We do not have any biosafety issue as we do not work with human viruses but focus on animal vaccine at the current stage which do not impose any risk to the lab or environment.
Reference
1. Merten O W. Introduction to animal cell culture technology—past, present and future [J]. Cytotechnology, 2006, 50(1-3): 1.
2. Tapia F, Vázquez-Ramírez D, Genzel Y, et al. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production [J]. Appl Microbiol Biotechnol, 2016, 100(5): 2121-2132.
3. Vlecken D H W, Pelgrim R P M, Ruminski S, et al. Comparison of initial feasibility of host cell lines for viral vaccine production [J]. Journal of Virological Methods, 2013, 193(1): 28-41.